Skip to main content

Therapies/Treatments

Results of a NIDA-supported pilot study released on Monday showed that collaboration between physicians and pharmacists could lead to improved medication adherence among patients being treated for opioid use disorder.
Spark Biomedical, a Texas-based medical device company, announced that the FDA has granted 510(k) clearance for its Sparrow Therapy System, a wearable neurostimulation device for the treatment of opioid withdrawal.
Patients diagnosed with depression who also have co-occurring substance use disorders are less likely to receive depression care in line with established best practices, according to a study by researchers from the University of Michigan and the VA Ann Arbor Healthcare System.
With the lethality, availability and use of stimulants all greatly increasing in the U.S. in recent years and the COVID-19 pandemic complicating the treatment landscape for patients and practitioners alike, it’s critical for providers to weather the storm, Deni Carise, PhD, chief science officer for Recovery Centers of America, told Cocaine, Meth & Stimulant Summit attendees in a Saturday session.
With methamphetamine and cocaine use on the rise across the U.S. and no medications as yet approved by the FDA, a combination of contingency management and community reinforcement is the most effective treatment modality for treating stimulant addiction, NIDA director Nora Volkow, MD, said in a Stimulant Summit keynote.
Back to Top